Key Highlights

  • Q3 Revenue reached a record $193.4 million, up 16% year over year.
  • Active patient counts rose 19%, driving Top Line growth.
  • Gross Margin stood at 77% with adjusted EBITDA of $15.7 million.
  • Full year 2026 revenue guidance raised to $736 million to $743 million and adjusted EBITDA guidance raised to $24 million to $34 million.

Patient Growth Drives Record Revenue

Novocure reported record third quarter revenue of $193.4 million, a 16% increase from the same period last year, driven by a 19% rise in active patient counts using the company's Tumor Treating Fields therapy. The company maintained a 77% gross margin for the quarter and generated adjusted EBITDA of $15.7 million, reflecting continued Operating Leverage as patient volumes expand.

Guidance Raised on Japanese Pancreatic Cancer Approval

Management lifted full year 2026 revenue guidance to a range of $736 million to $743 million and raised adjusted EBITDA guidance to $24 million to $34 million, reflecting steady momentum across existing indications. The improved outlook followed Japanese regulatory authorization of Optune Pax for locally advanced pancreatic cancer, which expands Novocure's commercial opportunity into a new indication and geography and adds to a growing list of approved uses for its Tumor Treating Fields technology.

What drove Novocure's record Q3 revenue?

Revenue growth was driven by a 19% increase in active patient counts, pushing total revenue to $193.4 million, up 16% year over year.

Why did Novocure raise its full year 2026 guidance?

The raised guidance followed Japanese regulatory authorization of Optune Pax for locally advanced pancreatic cancer, expanding the company's commercial runway.